J2407 Oritavancin (HCPCS) Reimbursement & Policy

HCPCS Level II code J2407 denotes an injection of oritavancin (Orbactiv), 10 mg, used for single-dose or multi-dose parenteral treatment of serious gram-positive infections. Nationally, accurate coding for long-acting antimicrobials matters for clinical continuity, pharmacy utilization, and outpatient infusion billing given oritavancin's unique dosing and cost profile. Payers commonly involved in coverage and reimbursement discussions include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.

Readers will learn how J2407 is used in clinical billing and service delivery, what typical sites of service are for oritavancin administration, and which payers are commonly relevant for coverage. The publication provides benchmarks for utilization and reimbursement patterns where available, highlights recent policy and coverage considerations affecting parenteral antimicrobial agents, and summarizes clinical context to aid coding accuracy. Data not available in the input is noted where applicable, and the content focuses on national-level implications for clinicians, coders, and payer policy analysts.

Billing Code Overview

HCPCS Level II code J2407 represents an injection of oritavancin (Orbactiv), 10 mg. This billing code is used to report administration of the antimicrobial agent oritavancin, a long-acting lipoglycopeptide antibiotic indicated for certain serious gram-positive bacterial infections.

Service type: injectable antimicrobial therapy

Typical site of service: outpatient infusion or clinic-based injection setting, including hospital outpatient departments, physician offices, and infusion centers where single-dose oritavancin is administered.

Clinical Context

A typical patient is an adult presenting to an outpatient infusion center or hospital outpatient department with a confirmed or suspected complicated Gram-positive bacterial skin and soft tissue infection (cSSTI) or other indicated Gram-positive infection requiring a single-dose long-acting intravenous lipoglycopeptide antibiotic. The patient often has one or more of the following: previous intolerance or failure of standard IV therapy (for example, vancomycin), limited venous access making multi-day therapy impractical, social factors limiting outpatient parenteral antibiotic therapy adherence, or a need to avoid prolonged hospitalization.

Workflow:

Initial evaluation in emergency department, clinic, or inpatient ward including history, physical exam, and wound assessment.
Obtain cultures (blood and wound) and baseline labs (CBC, renal and hepatic panels) to assess suitability for oritavancin.
Allergy review and verification that no concurrent intravenous unfractionated heparin is required within 120 hours due to interference with coagulation tests.
Prescribing clinician orders J2407 for oritavancin, documents indication (e.g., cSSTI, cellulitis), and selects appropriate site of service (outpatient infusion center, hospital outpatient department, or inpatient when clinically indicated).
Pharmacy prepares the single-dose infusion per manufacturer and institutional protocols; nursing verifies identity, informs patient about potential infusion-related reactions, and administers per infusion instructions.
Monitor vital signs during and after infusion for infusion-related reactions and monitor coagulation tests interpretation as needed for up to 120 hours post-dose.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier — default billing indicator	Use when no additional modifier applies to the service for payor reporting.
`11`	Professional component	Use when billing only the professional interpretation component if applicable (rare for drug codes).
`22`	Increased procedural services	Use when substantially greater services are provided (e.g., extended monitoring due to infusion reaction) and supported by documentation.
`23`	Unusual anesthesia	Not typically used for infusion drugs; use only if unusual anesthesia services were required during administration.
`52`	Reduced services	Use if an abbreviated infusion or partial service was provided relative to the full service.
`62`	Two surgeons	Not applicable in most infusion scenarios; use only if two qualified providers bill for distinct services tied to the infusion procedure.
`78`	Unplanned return to OR by same physician following initial procedure	Not typically applicable to drug administration; include only if an infusion-related surgical procedure occurred.
`80`	Assistant surgeon	Not applicable for drug administration unless an assistant surgeon is legitimately billing for a concurrent service.
`AS`	Physician assistant, nurse practitioner, or clinical nurse specialist services	Use when the service was performed by a qualified non-physician practitioner operating within scope and billing rules permit.
`JW`	Drug wasted/discarded	Use when part of the single-dose vial was discarded and payer requires reporting of discarded portion for payment adjustment.
`JZ`	No drug administered — patient refused	Use when medication was ordered but not administered due to patient refusal.
`QX`	Modifier certifying that services were performed by a PA under supervision of a physician	Use when a physician assistant performed the infusion and attestation is required by payer.
`QY`	Services performed by a PA under physician supervision per state law	Use when required to indicate physician supervision level.
`U8`	COVID-19 public health emergency related	Use only if the service is being reported with emergency-specific reporting requirements tied to the code; verify payer guidance.

Taxonomy Code	Specialty	Notes
363A00000X	Infectious Disease	Specialists who may prescribe and oversee complex antimicrobial therapies.
207K00000X	Internal Medicine	Hospitalists and internists managing inpatients requiring single-dose long-acting antibiotics.
184400000X	Registered Nurse	Infusion nurses who prepare and administer IV antibiotics in outpatient infusion centers.
163W00000X	Emergency Medicine	Emergency physicians who initiate single-dose therapy and may arrange outpatient administration.
208D00000X	Family Medicine	Primary care or urgent care physicians managing community-acquired skin infections and coordinating infusion therapy.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`L03.116`	Cellulitis of right lower limb	Cellulitis is a common cSSTI indication for single-dose IV lipoglycopeptide therapy when Gram-positive pathogens are suspected.
`L03.115`	Cellulitis of left lower limb	Cellulitis of lower extremities often necessitates IV antibiotics when severe or systemic signs are present.
`L03.019`	Cellulitis of unspecified upper limb	Upper limb cellulitis represents another typical indication for IV therapy targeting Gram-positive organisms.
`A41.9`	Sepsis, unspecified organism	In select clinically appropriate cases with Gram-positive bacteremia, oritavancin may be considered per infectious disease guidance.
`L02.211`	Cutaneous abscess of right lower limb	Abscesses with surrounding cellulitis may be treated with single-dose long-acting IV antibiotics when incision and drainage plus systemic therapy are indicated.
`L02.211`	Cutaneous abscess of left lower limb	(If bilateral or contralateral) Abscess diagnoses frequently accompany cSSTI treatment decisions.
`B95.6`	Methicillin resistant Staphylococcus aureus infection as the cause of diseases classified elsewhere	MRSA is a principal Gram-positive pathogen for which oritavancin has activity; coding as a causal organism is reported when known.
`Z79.2`	Long term (current) use of antibiotics	May be used in documentation when ongoing antibiotic therapy considerations are present, though oritavancin is single-dose therapy.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`96365`	Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour	Commonly used to report the infusion administration time for an IV antibiotic when initial infusion time falls within 1 hour.
`96366`	Intravenous infusion, each additional hour	Used if infusion time for oritavancin extends beyond the first hour and payer requires reporting of extended infusion time.
`96372`	Therapeutic, prophylactic, or diagnostic injection (specify substance or drug); subcutaneous or intramuscular	May be used if institutional practice administers medication by IM route (oritavancin is IV — include only if an alternative route is documented, generally not applicable).
`36415`	Collection of venous blood by venipuncture	Performed for baseline labs and culture draws prior to or after infusion.
`99070`	Supplies and materials (e.g., drugs requiring additional supplies when not included with the main service)	Used to report additional non-billable supplies related to infusion if payer permits separate charging.

OpenPayer

Summary & Overview

HCPCS Level II J2407: Oritavancin (Orbactiv) Injection, 10 mg